All Title Author
Keywords Abstract

PLOS ONE  2012 

Complement Inhibition Promotes Endogenous Neurogenesis and Sustained Anti-Inflammatory Neuroprotection following Reperfused Stroke

DOI: 10.1371/journal.pone.0038664

Full-Text   Cite this paper   Add to My Lib


Background and Purpose The restoration of blood-flow following cerebral ischemia incites a series of deleterious cascades that exacerbate neuronal injury. Pharmacologic inhibition of the C3a-receptor ameliorates cerebral injury by attenuating post-ischemic inflammation. Recent reports also implicate C3a in the modulation of tissue repair, suggesting that complement may influence both injury and recovery at later post-ischemic time-points. Methods To evaluate the effect of C3a-receptor antagonism on post-ischemic neurogenesis and neurological outcome in the subacute period of stroke, transient focal cerebral ischemia was induced in adult male C57BL/6 mice treated with multiple regimens of a C3a receptor antagonist (C3aRA). Results Low-dose C3aRA administration during the acute phase of stroke promotes neuroblast proliferation in the subventricular zone at 7 days. Additionally, the C3a receptor is expressed on T-lymphocytes within the ischemic territory at 7 days, and this cellular infiltrate is abrogated by C3aRA administration. Finally, C3aRA treatment confers robust histologic and functional neuroprotection at this delayed time-point. Conclusions Targeted complement inhibition through low-dose antagonism of the C3a receptor promotes post-ischemic neuroblast proliferation in the SVZ. Furthermore, C3aRA administration suppresses T-lymphocyte infiltration and improves delayed functional and histologic outcome following reperfused stroke. Post-ischemic complement activation may be pharmacologically manipulated to yield an effective therapy for stroke.


[1]  Zipfel PF, Skerka C (2009) Complement regulators and inhibitory proteins. Nat Rev Immunol 9: 729–740.
[2]  Drouin SM, Kildsgaard J, Haviland J, Zabner J, Jia HP, et al. (2001) Expression of the complement anaphylatoxin C3a and C5a receptors on bronchial epithelial and smooth muscle cells in models of sepsis and asthma. J Immunol 166: 2025–2032.
[3]  Gasque P, Singhrao SK, Neal JW, Wang P, Sayah S, et al. (1998) The receptor for complement anaphylatoxin C3a is expressed by myeloid cells and nonmyeloid cells in inflamed human central nervous system: analysis in multiple sclerosis and bacterial meningitis. J Immunol 160: 3543–3554.
[4]  Atkinson C, Zhu H, Qiao F, Varela JC, Yu J, et al. (2006) Complement-dependent P-selectin expression and injury following ischemic stroke. J Immunol 177: 7266–7274.
[5]  Arumugam TV, Woodruff TM, Lathia JD, Selvaraj PK, Mattson MP, et al. (2008) Neuroprotection in stroke by complement inhibition and immunoglobulin therapy. Neuroscience.
[6]  Mocco J, Sughrue ME, Ducruet AF, Komotar RJ, Sosunov SA, et al. (2006) The complement system: a potential target for stroke therapy. Adv Exp Med Biol 586: 189–201.
[7]  Ducruet AF, Hassid BG, Mack WJ, Sosunov SA, Otten ML, et al. (2008) C3a receptor modulation of granulocyte infiltration after murine focal cerebral ischemia is reperfusion dependent. J Cereb Blood Flow Metab 28: 1048–1058.
[8]  Markiewski MM, Mastellos D, Tudoran R, DeAngelis RA, Strey CW, et al. (2004) C3a and C3b activation products of the third component of complement (C3) are critical for normal liver recovery after toxic injury. J Immunol 173: 747–754.
[9]  DeAngelis RA, Markiewski MM, Lambris JD (2006) Liver regeneration: a link to inflammation through complement. Adv Exp Med Biol 586: 17–34.
[10]  Kimura Y, Madhavan M, Call MK, Santiago W, Tsonis PA, et al. (2003) Expression of complement 3 and complement 5 in newt limb and lens regeneration. J Immunol 170: 2331–2339.
[11]  Rahpeymai Y, Hietala MA, Wilhelmsson U, Fotheringham A, Davies I, et al. (2006) Complement: a novel factor in basal and ischemia-induced neurogenesis. Embo J 25: 1364–1374.
[12]  Ames RS, Lee D, Foley JJ, Jurewicz AJ, Tornetta MA, et al. (2001) Identification of a selective nonpeptide antagonist of the anaphylatoxin C3a receptor that demonstrates antiinflammatory activity in animal models. J Immunol 166: 6341–6348.
[13]  Proctor LM, Arumugam TV, Shiels I, Reid RC, Fairlie DP, et al. (2004) Comparative anti-inflammatory activities of antagonists to C3a and C5a receptors in a rat model of intestinal ischaemia/reperfusion injury. Br J Pharmacol 142: 756–764.
[14]  Mocco J, Mack WJ, Ducruet AF, Sosunov SA, Sughrue ME, et al. (2006) Complement component C3 mediates inflammatory injury following focal cerebral ischemia. Circ Res 99: 209–217.
[15]  Connolly ES Jr, Winfree CJ, Stern DM, Solomon RA, Pinsky DJ (1996) Procedural and strain-related variables significantly affect outcome in a murine model of focal cerebral ischemia. Neurosurgery 38: 523–531; discussion 532.
[16]  Encinas JM, Enikolopov G (2008) Identifying and quantitating neural stem and progenitor cells in the adult brain. Methods Cell Biol 85: 243–272.
[17]  Ten VS, Bradley-Moore M, Gingrich JA, Stark RI, Pinsky DJ (2003) Brain injury and neurofunctional deficit in neonatal mice with hypoxic-ischemic encephalopathy. Behav Brain Res 145: 209–219.
[18]  Rynkowski MA, Kim GH, Garrett MC, Zacharia BE, Otten ML, et al. (2009) C3a receptor antagonist attenuates brain injury after intracerebral hemorrhage. J Cereb Blood Flow Metab 29: 98–107.
[19]  Bouet V, Freret T, Toutain J, Divoux D, Boulouard M, et al. (2007) Sensorimotor and cognitive deficits after transient middle cerebral artery occlusion in the mouse. Exp Neurol 203: 555–567.
[20]  Winter B, Bert B, Fink H, Dirnagl U, Endres M (2004) Dysexecutive syndrome after mild cerebral ischemia? Mice learn normally but have deficits in strategy switching. Stroke 35: 191–195.
[21]  Hua Y, Schallert T, Keep RF, Wu J, Hoff JT, et al. (2002) Behavioral tests after intracerebral hemorrhage in the rat. Stroke 33: 2478–2484.
[22]  Bogestal YR, Barnum SR, Smith PL, Mattisson V, Pekny M, et al. (2007) Signaling through C5aR is not involved in basal neurogenesis. J Neurosci Res 85: 2892–2897.
[23]  Moriyama M, Fukuhara T, Britschgi M, He Y, Narasimhan R, et al. (2011) Complement receptor 2 is expressed in neural progenitor cells and regulates adult hippocampal neurogenesis. J Neurosci 31: 3981–3989.
[24]  Jean WC, Spellman SR, Nussbaum ES, Low WC (1998) Reperfusion injury after focal cerebral ischemia: the role of inflammation and the therapeutic horizon. Neurosurgery 43: 1382–1396; discussion 1396-1387.
[25]  Yamashita T, Ninomiya M, Hernandez Acosta P, Garcia-Verdugo JM, Sunabori T, et al. (2006) Subventricular zone-derived neuroblasts migrate and differentiate into mature neurons in the post-stroke adult striatum. J Neurosci 26: 6627–6636.
[26]  Jin K, Minami M, Lan JQ, Mao XO, Batteur S, et al. (2001) Neurogenesis in dentate subgranular zone and rostral subventricular zone after focal cerebral ischemia in the rat. Proc Natl Acad Sci U S A 98: 4710–4715.
[27]  Sun Y, Jin K, Xie L, Childs J, Mao XO, et al. (2003) VEGF-induced neuroprotection, neurogenesis, and angiogenesis after focal cerebral ischemia. J Clin Invest 111: 1843–1851.
[28]  Kuge A, Takemura S, Kokubo Y, Sato S, Goto K, et al. (2009) Temporal profile of neurogenesis in the subventricular zone, dentate gyrus and cerebral cortex following transient focal cerebral ischemia. Neurol Res 31: 969–976.
[29]  Mathieu P, Battista D, Depino A, Roca V, Graciarena M, et al. (2009) The more you have, the less you get: the functional role of inflammation on neuronal differentiation of endogenous and transplanted neural stem cells in the adult brain. J Neurochem.
[30]  Ben-Hur T, Ben-Menachem O, Furer V, Einstein O, Mizrachi-Kol R, et al. (2003) Effects of proinflammatory cytokines on the growth, fate, and motility of multipotential neural precursor cells. Mol Cell Neurosci 24: 623–631.
[31]  Stevens SL, Bao J, Hollis J, Lessov NS, Clark WM, et al. (2002) The use of flow cytometry to evaluate temporal changes in inflammatory cells following focal cerebral ischemia in mice. Brain Res 932: 110–119.
[32]  Wang T, Lee MH, Johnson T, Allie R, Hu L, et al. (2010) Activated T-cells inhibit neurogenesis by releasing granzyme B: rescue by Kv1.3 blockers. J Neurosci 30: 5020–5027.
[33]  Saver JL, Albers GW, Dunn B, Johnston KC, Fisher M (2009) Stroke Therapy Academic Industry Roundtable (STAIR) recommendations for extended window acute stroke therapy trials. Stroke 40: 2594–2600.


comments powered by Disqus